RxDoctor Payments Data

Justin Heath, DO

Family Medicine · Fallon, NVNPI 1295939163

Payments from drug & device makers

$683in general payments, 2019–2025

Across 40 payments — averaging $17.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$162
  • Supernus Pharmaceuticals, Inc.$126
  • Boehringer Ingelheim$69
  • AstraZeneca$64
  • Merck$54
  • GSK$38
  • plus $170 from 9 others

What the payments were for

  • Food & beverage$66998%
  • Education$142%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$683 in reported general payments places this provider in the 60th percentile of 902 family medicine providers in Nevada.

See all family medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$111,381
Medicare patients
440
Services billed
1,270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin78$84,875
EliquisApixaban82$84,137
OzempicSemaglutide66$73,296
TrulicityDulaglutide62$73,262
XareltoRivaroxaban60$52,308
Breo ElliptaFluticasone/Vilanterol42$28,415
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$24,057
Breztri AerosphereBudesonide/Glycopyr/Formoterol26$22,424
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog31$18,222
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr28$16,058
Stiolto RespimatTiotropium Br/Olodaterol Hcl19$15,242
JanuviaSitagliptin Phosphate17$14,866
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$11,229
Incruse ElliptaUmeclidinium Bromide26$10,636
Tresiba Flextouch U-100Insulin Degludec16$10,483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat, Spiriva Respimat$69$110,125109 claims
PfizerEliquis$162$84,13782 claims
GSKBreo Ellipta, Trelegy Ellipta, Anoro Ellipta, Incruse Ellipta$38$79,166122 claims
Novo NordiskOzempic$28$73,29666 claims
AstraZenecaBreztri Aerosphere, Symbicort$64$25,08238 claims
MerckJanuvia$54$14,86617 claims
AbbVieSynthroid$16$1,98733 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 902 family medicine providers in Nevada.

Other family medicine in Fallon

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →